Clover Health Investments (NASDAQ:CLOV) Third Quarter 2024 Results

Key Financial Results

• Revenue: US$331.0m (down 31% from 3Q 2023).
• Net loss: US$8.79m (loss narrowed by 79% from 3Q 2023).
• US$0.018 loss per share (improved from US$0.086 loss in 3Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Clover Health Investments EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 4.4%. Earnings per share (EPS) exceeded analyst estimates by 54%.

Looking ahead, revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Healthcare industry in the US.

Performance of the American Healthcare industry.

The company's shares are down 11% from a week ago.

Risk Analysis

Be aware that Clover Health Investments is showing 2 warning signs in our investment analysis and 1 of those is a bit concerning...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.